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Abstract
Background and Purpose—The ability to assess tumor malignancy and to monitor treatment
response non-invasively would be of value to both clinicians and animal investigators. This report
describes the MR imaging characteristics of a genetically engineered mouse model of choroid plexus
carcinoma (CPC) during tumor growth and progression to malignancy. We assess the ability of vessel
tortuosity measurements, as calculated from high-resolution MRA images, to detect emerging CPC
cancers.
Methods—MR images were analyzed of 9 healthy mice and of 20 CPC mice with precancerous
choroid dysplasia or with cancer over a wide range of sizes. Two vessel tortuosity measures and a
measure of vessel density (vessel count) were calculated from MRA images. Malignancy assessment
was based upon a statistical analysis of vessel tortuosity, using an equation derived from an earlier
study of human brain tumor patients.
Results—Choroid dysplasia was correctly judged non-malignant. On the basis of vessel count, neo-
angiogenesis could not be detected until cancers were full-blown and had reached a volume of
approximately 80mm3. Vessel tortuosity measurements, however, correctly identified emerging
malignancy in lesions larger than 0.3mm3.
Conclusion—This report provides the first description of in vivo, MR imaging characteristics of
genetically engineered CPC mice during the progression from dysplasia to cancer. Vessel tortuosity
measurements offer promise of correctly defining even tiny tumors as malignant.
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The ability to assess tumor malignancy and to monitor treatment response non-invasively
would be of high value in the treatment of human brain tumors. Unfortunately, despite the
development of multiple imaging modalities, reliable assessment of both tumor malignancy
and therapeutic response remains problematic (1,2,3,4). Particular difficulty may be
encountered with the classification of small tumors.
This paper describes a new approach that quantifies vessel shape as measured from high-
resolution magnetic resonance angiographic (MRA) images. An intriguing observation made
by those working from histological sections is that malignancy induces characteristic vascular
morphological changes, described as “…a profound sort of tortuosity, with many smaller bends
upon each larger bend” (5). X-ray angiographers have also noted that malignancy tends to be
associated with “irregular coursing of vessels” of “bizarre configuration” (6). This abnormal
tortuosity may be related to increases in nitrous oxide induced by VEGF (7), and is found in
a wide variety of malignant tumors including those of the breast (8), brain (9), colon (10), and
lung (11).
Important to those interested in MR imaging, these morphological abnormalities are neither
confined to tiny, new capillary sprouts nor are restricted to tumors of large size. Instead, these
morphological changes occur very early during malignant tumor growth, appear within 24
hours of injection of a few tens of cancer cells in animal xenograft models, and affect initially
healthy vessels that course far beyond tumor confines (12). Of additional importance,
successful treatment induces rapid normalization of the associated vessel tortuosity
abnormalities (12,13), suggesting that quantitative monitoring of these vascular shape changes
could provide an effective means of assessing treatment response (14). Equally importantly,
cancer-associated changes to vessel shape do not appear to simply mirror the degree of tissue
vascularity depicted by perfusion imaging, but rather provide complementary information
(15).
Our group has developed quantitative measures of vessel tortuosity that can be applied to
vessels defined from MRA images (16). In a recent blinded study of 30 human brain tumors
imaged prior to total gross resection of each lesion, all tumors but one were correctly judged
benign or malignant on the basis of vessel shape (17). This study included a variety of tumors
difficult to classify by other means, and included hypervascular benign tumors, irradiated and
necrotic cancers, and hemorrhagic lesions.
An important and unresolved issue, however, is how large a tumor must be before cancer-
associated vessel shape changes can be perceived by MRA. All of the tumors evaluated in the
blinded study were either at least moderately large (1 cm3 or greater) or presented as a miniscule
additional lesion in a patient with a much larger tumor. If very tiny lesions could be classified
correctly as benign or malignant, a method based upon vessel shape analysis might be used to
screen patients for emerging new tumors. The determination of how large a cancer must be
before MRA images can capture vessel shape abnormalities is difficult to define in human
subjects, however, since whole-brain histological information is not available and tiny lesions
are only rarely biopsied.
A logical means of addressing this question is to employ genetically engineered mouse models.
In these murine tumor models, the manipulation of genes known to be associated with particular
cancers induces tumors that arise spontaneously and in the appropriate anatomical locations
(18,19,20). Unlike human subjects, however, whole brain histological information is available
so that the information provided by histology can be used to assess the accuracy of any proposed
non-invasive imaging method.
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The current study evaluates vascular morphological changes associated with a well-
characterized, genetically engineered mouse model of choroid plexus carcinoma (CPC). In this
model, mice are born apparently healthy. At approximately three weeks of age mice develop
choroid dysplasia that, at about five weeks, progresses to the development of tiny, solid,
spherical, non-infiltrating cancers and then to massive lesions that become life-threatening at
about twelve weeks. This progression of a non-infiltrating, brain-displacing cancer from a
microscopic to a huge malignancy simulates the growth of a metastatic lesion, but the
genetically engineered mouse model provides conditions under which a cancer is guaranteed
to emerge at approximately known time and location.
The purpose of this paper is two-fold. First, we describe the MR imaging characteristics of
emerging CPC tumors in genetically engineered mice. Although a previous publication has
described the MR appearance of massive CPC tumors (21), the current report is, to our
knowledge, the first to describe the MR imaging characteristics of these genetically engineered
tumors as they dedifferentiate and grow.
Second, we assess a new method of grading tumor malignancy in detecting small tumors. This
method defines vessels mathematically from MRA images and calculates quantitative
measures of tortuosity. In human subjects, we have defined a statistical “malignancy
probability” (MP) equation that, for each test subject, compares vessel tortuosity values within
a region of interest to the vessel tortuosity values calculated over the same anatomical region
of a set of healthy subjects (17). Questions to be answered by the current study are 1) whether
the MP equation derived from human subjects can correctly classify mice with choroid
dysplasia as having benign disease, 2) whether the same equation can correctly classify mice
with large tumors as having cancer, and 3) how large an emerging cancer must be before MRA
imaging can successfully define a sufficient degree of tortuosity abnormality for the MP
equation to define the emerging lesion as malignant. If predictive, such studies in a defined
preclinical model could be used to refine the detection of human malignancy and could be
instrumental in assessing preclinical therapeutic responses.
METHODS
This report analyzes the images of nine healthy mice and of twenty CPC (TgT121;p53+/−) mice
ranging from three weeks to four months of age. The work was approved by the UNC
Institutional Animal Care and Use Committee.
Animal tumor subjects
The TgT121;p53+/− mouse is derived by mating a B6.D2-Tg(LPV-TagT121)tvd mouse
(TgT121) with a B6.129S2-Trp53tm1Tyj mouse (p53−/−). Genotype is determined by PCR
(polymerase chain reaction) as previously described (23). The TgT121 mouse is on a mixed
background of approximately 50% C57BL/6J (B6) and 50% DBA/2J (DBA/2J). The p53−/−
mouse is on a 100% C57BL/6J background such that TgT121;p53+/− mice are approximately
75% C57BL/6J and 25% DBA/2J.
Specifically in choroid plexus epithelium, TgT121 mice express a truncated 121-amino acid
SV40 T antigen mutant that binds to and inactivates the tumor suppressor pRb and related
proteins p107 and p130. This induces dysplasia by 3 weeks of age, which progresses over time
to CPC. Progression is accelerated in a p53+/− background, and occurs within a reproducible
timeframe of 6–8 weeks with clonal loss of p53. By postmortem histological assessment,
multiple such CPC foci can be detected within the CPC, with one or more tumors becoming
massive and life-threatening by 12 weeks of age. Penetrance of this phenotype is 100 % (22,
23).
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For the current study, ten mice were imaged at a stage at which large or moderately large tumors
were expected (8–12 weeks) and ten mice were imaged at an earlier stage (3–7 weeks) likely
to show either no cancer or early cancer development. One subject was imaged twice, first at
an early and then at a late stage.
MR imaging
All images were acquired on a Siemens 3T Allegra head only scanner (Siemens Medical Inc.,
Erlangen, Germany) with a maximum gradient strength of 40 mT/m and a slew rate of 400
mT/m/msec. A custom-made volume coil measuring 2.1 cm in diameter was utilized. Imaging
sequences included a pre-contrast 3D T1W sequence (30mm2 FOV, 0.1x0.1x1.0mm3 voxel
size, TR 500ms, TE 13ms, 4 averages, and TA 8:46) and a T2W sequence (30mm2 FOV,
0.1x0.1x1.0mm3 voxel size, TR 6990ms, TE 100ms, 4 averages, and TA 11:20). A high-
resolution, non-contrast, 3D time-of-flight (TOF) MRA sequence was employed for acquiring
MRA images (17mm2 FOV, 0.1x0.1x0.1 mm3 voxel size, TR 53 msec, TE 8.79 msec, 2
averages, 256x256 resolution, and TA 23:11). Following an intra-peritoneal injection of 0.5
mL Gadolinium enhanced T1W images were acquired with identical parameters as above.
Total image acquisition time was approximately 1 hour.
Isoflurane, an inhalant anesthesia, was mixed with air and administered to animals at 2%
induction and 1% maintenance through a nose cone. All mice were stereotactically
immobilized prior to imaging.
Image processing
Following image acquisition, all images were transferred to a computer for postprocessing.
Image processing time was approximately 1.5 hours. Details of the imaging processing
methods and of the statistical approach employed are given in the Appendix. In brief, the
approach involved a computerized, statistical comparison of measures of vessel shape between
the 9 healthy mice and each of the 20 test subjects over an anatomical region of interest. For
tumors greater than 50 mm3 the region of interest was delineated by the tumor margins itself;
for smaller tumors or if no tumor was evident by MR the region of interest was taken to be the
lateral and third ventricles. Tumor volumes were additionally calculated if a tumor was visible
by MR, regardless of tumor size. Each tumor animal’s vessel shape parameters were
normalized (z-scored) by the means and standard deviations of the healthy mouse values.
Results here are reported for the following parameters in each tumor mouse:
Tumor Volume (TV): Tumor volume in cubic mm. For animals with more than one tumor
delineable by MR, the TV is given as the total tumor volume in that mouse.
Normalized vessel count (nVC): The vessel count gives the number of individual, unbranched
vessels contained within or passing through a region of interest. Output is an integer. The VC
provides a measure of vessel density as seen by MRA. When normalized, a value of -1 implies
a count one standard deviation below the healthy mean, and a value of 2 a count 2 standard
deviations above the healthy mean.
Normalized Sum of Angles Metric (nSOAM): The SOAM is a tortuosity measure that is
elevated in the presence of high-frequency, low-amplitude vessel sine waves or coils. The
SOAM sums the angles between consecutive trios of points along a space curve and normalizes
by the path length (16). The SOAM for a region of interest is expressed as the average SOAM
of the vessels lying within that region. Results are output as radians/mm. The SOAM value is
almost invariably elevated for cancer-associated vasculature.
Normalized Inflection Count Metric (nICM): The ICM is a tortuosity measure that measures
larger amplitude curves than SOAM. The ICM counts “inflection points” along each space
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curve and multiplies this number (plus one) times the total path length and then divides by the
distance between endpoints. For a 3D space curve, we define an inflection point as a locus that
exhibits a minimum of total curvature. In particular, the Normal and Binormal axes of the
Frenet frame (24) change orientation by close to 180o as the frame passes through an inflection
point. As a result, one can search for 3D inflection points by identifying large local maxima
of the dot product N N, where N is the unit vector representing the Frenet normal axis, and
N represents the difference of the normal axes associated with the consecutive points Pk and
Pk+1. The ICM for a region of interest is expressed as the average ICM of the vessels lying
within that region. Results are output as a dimensionless number (16). The ICM value is often
elevated in the presence of cancer.
Malignancy Probability (MP): The probability of malignancy on a scale of 0% to 100%, given
by an equation that employs nSOAM and nICM (17). A value greater than 60% is viewed as
indicative of malignancy, a value less than 40% is viewed as indicative of benign disease, and
a value of 40–60% is considered indeterminate.
Histology
Mouse brains were fixed in 10% formalin and embedded in paraffin. Early in the study, mouse
brains were cut in half along the sagittal midline and sectioned for 10 successive layers using
sagittal sections at 50 μm intervals, as has been customary for the Van Dyke group (23). Later
in the study, one or more regions of interest were selected from inspection of the mouse’s MR
images, and the mouse brain was sectioned at 50 μm intervals within these regions. For these
later studies, the plane of section was coronal in order to approximately match the plane of cut
of the MR images. A 5μm section from each layer was then stained with hematoxylin and
eosin.
RESULTS
Imaging characteristics of CPC mice during tumor development
In TgT121;p53+/− mice, the first step toward tumor development is the emergence of choroid
dysplasia. Figure 1 illustrates T1, T2 and MRA slices from an animal with choroid dysplasia,
as well as a histological section taken from this animal and a 3D rendering of the segmented
vessels. We were not able to detect the presence of choroid dysplasia on the basis of either MR
imaging or by vessel analysis in any such animal, and both the MR images and the segmented
vessels appeared normal.
As choroid dyplasia progresses into cancer, tiny foci of tumor appear within the ventricular
system, resembling peas lying within a ventricular pod. Although tiny, these tumors are highly
malignant. These cancers are often best perceived on T2 images, in which they appear as filling
defects against the bright white of the CSF (Figure 2). Gadolinium-enhanced T1 images do not
demarcate these tiny lesions well. Since we were not able to define tiny tumors on more than
one slice, the ventricular system was again taken as the region of interest. We were unable to
appreciate any increase in vessel count by MRA imaging at this stage of tumor development.
However, even though these tumors were very small, the associated vessels exhibited severe
tortuosity abnormalities, indicative of high malignancy (Figure 3).
Figure 3 provides an example of the typical kind of vessel tortuosity abnormality seen with
malignancy. Whereas healthy vessels tend to bend and curve along relatively smooth paths,
cancer-associated vasculature tends to exhibit “many smaller bends upon each larger
bend” (5).
Once cancer is established, growth is rapid and leads to the emergence of massive cancers that
occupy close to the entire ventricular system, expand the skull, and produce death within a
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matter of weeks. Figure 4 provides an example of this kind of massive tumor. Note that these
large intra-ventricular tumors can again be defined well on T2 images but now can also be
defined as well or better on gadolinium-enhanced T1 images, in which the tumor now enhances
relative to brain and is often surrounded by a brighter shell of CSF (Figure 4). By vessel analysis
of the MRA images, all such tumors exhibited an increase in vessel number and also displayed
severe vessel tortuosity abnormalities indicative of malignancy.
Vessel attribute analysis
Table 1 provides a summary of vessel attribute values for each animal, sorted by total tumor
volume. Normalized (z-scored) VC, SOAM, and ICM values are given for each mouse, as is
the overall assessment of malignancy calculated via vessel tortuosity. The number of discrete
tumors visualized by MR is also provided, as is a brief description of tumor presentation.
Tumors are here classified by volume into four categories: huge (>120 mm3), large (50 – 120
mm3), small (1 – 50 mm3), and tiny (<1 mm3).
As indicated by Table 1, tumors could reach massive size. For those tumors with a volume
greater than approximately 80 mm3, we could detect significant increases in vessel density as
measured by the normalized VC. We were unable to detect a significant increase in vessel
number in tumors smaller than 50 mm3 as imaged by MRA, however, and these tumors
generally exhibited a VC within one standard deviation of normal.
Vessel tortuosity measurements indicated a high probability of malignancy, however, not only
for large tumors but also for those <50 mm3. Indeed, the malignancy probability estimates were
equivalent for all tumors greater than 1 mm3, as is consistent with the histology of these cancers.
The limit of vessel tortuosity assessment in detecting malignancy in these CPC tumors appears
to occur with tumor volumes in the range of 0.3 – 1 mm3. In one mouse with a tumor volume
of 1.1 mm3 the malignancy probability was correctly calculated to be 99%. However, in two
mice with single tiny tumors (0.3 mm3) the malignancy probability assessment was
indeterminate in one case and provided a false negative in the second.
DISCUSSION
This report discusses the MR characteristics of a well-characterized, genetically engineered
mouse model of choroid plexus carcinoma during tumor growth and progression. The majority
of research addressing the imaging of tumor-associated vasculature has focused upon
microvasculature and vascular density. By contrast, the current report focuses upon the vessel
shape changes associated with vessels individually discernible from high-resolution MRA.
CPC tumors are heavily neo-angiogenic. All five of the cancers larger than 120 mm3 analyzed
in this report exhibited massive increase in the number of vessels visualized by MRA, with a
mean vessel count more than 6 standard deviations above the healthy mean. These results are
consistent with our previous report based upon manual vessel counts on histological sections,
in which terminal animals were found to have vessels counts 7 standard deviations above those
of animals sacrificed at an early age (23). The current study was unable to detect a significant
increase in vessel number for small tumors, however, and almost all animals with a tumor
volume less than 50 mm3 exhibited a vessel count within one standard deviation of that found
in healthy mice. This result also appears consistent with vessel counts performed on histological
sections of animals with small tumors (Yin and Van Dyke, in progress). However, the lack of
change in vessel count by MRA of small tumors could also reflect the inability of this method
to visualize vessels of diameter smaller than that of the voxel size used during image
acquisition; the neo-angiogenic vessels lying within or supplying small tumors are themselves
likely to be small.
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Far more interesting is the result of vessel tortuosity measurement and the application of a
malignancy probability equation derived from these tortuosity values. Even if MRA imaging
is incapable of detecting an increase in vessel number for small tumors, our results suggest that
a statistical analysis of vessel tortuosity may correctly identify the presence of tiny cancers for
tumors larger than approximately 0.3mm3. These findings are consistent with those of Li et.
al. (12), who illustrate that cancer-associated vessel tortuosity changes affect initially healthy
vessels and are not restricted to just tiny, neo-angiogenic sprouts within the capillary bed.
The use of vessel tortuosity measures to monitor tumor progression and therapeutic response
is appealing for several reasons. First, like many other imaging procedures, the method is
entirely noninvasive. Second, the fact that vessel tortuosity abnormalities occur even in tiny
malignancies, spread beyond the confines of a cancer’s margins, and affect vessels much larger
than those of the capillary bed (12) means that tortuosity assessment has the potential of
recognizing even tiny tumors as malignant, which has been a difficult problem for many
alternative techniques. Third, the development of vessel tortuosity abnormalities does not
appear to be directly related to blood flow (15). Vessel tortuosity analysis thus may offer a
complementary approach to perfusion imaging. Fourth, abnormal vessel tortuosity resolves
rapidly with effective treatment (7,12,13), making the approach potentially useful for rapid
assessment of treatment in human subjects and for therapeutic development and assessment in
preclinical murine models.. Finally, the vessel shape changes characteristic of malignancy
occur in cancers throughout the human body and across species, making the general approach
potentially applicable to a wide variety of applications.
Given a mathematical description of segmented vessels, a wide variety of vessel attributes are
potentially available for analysis. The current report examines only vessel count and two
tortuosity measures, since these are the three attributes that have seemed most useful when
analyzing human brain tumor patients. Additional parameters such as average vessel radius,
change in radius, branching frequency, branching angle, and a variety of other vessel attributes
might be useful in analyzing other disease processes or in following an individual over time.
An advantage of the proposed approach is that it is immediately extensible to an arbitrary
number of parameters.
A limitation of the technique is that tortuosity assessment requires delineation of the paths of
individual vessels. It is therefore impossible to incorporate information about vessels whose
diameters are smaller than those of the voxels employed during image acquisition. This study
employed non-enhanced MRA images. Although gadolinium enhancement can increase the
number of vessels visualized by MRA, it also tends to opacify large CPC tumors, making it
difficult or impossible to define vessels within the tumor margins. This study therefore did not
employ gadolinium-enhanced MRA. Computed tomographic angiography (CTA) can
visualize smaller vessels than MRA. We did not employ CTA, however, because our approach
is based upon a statistical comparison of vessel numbers and shapes across subjects. The
difference in circulation times between different individuals makes CTA injection timing
difficult. For our purposes, if the injection were timed too late it might miss the small vessels
critical to our approach, and if timed too early it would be likely to “white out” the tumor,
making it impossible to discriminate individual vessels within the tumor boundaries. Moreover,
MR is more sensitive to tumor delineation than is CT. MR/MRA therefore seemed a better
choice for the current study.
A second limitation of the technique, as currently implemented, is that it requires delineation
of a region of interest. When a tumor is large and readily perceptible on MR it is reasonable
to take the tumor margins as the region of interest, as we have done in human subjects (17)
and in the largest of the murine CPC tumors evaluated in the current report. When searching
for very tiny tumors, the genetically engineered CPC mouse model has the particular advantage
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that emerging cancers are restricted to the ventricular system, and so the ventricles can be used
as the region of interest. For human patients, however, the location of an emerging metastasis
or other cancer cannot be predicted in advance. A global search for emerging cancer using
measurements of focal vessel shape abnormalities will thus require the creation of an atlas of
healthy subjects, in which each voxel contains local vessel shape statistics. Such an atlas is
currently under development for the brains of human subjects.
Since our approach cannot image capillaries, it would be of interest to compare perfusion
imaging with vessel tortuosity assessment, and possibly to include perfusion imaging
characteristics as one of the vessel attributes. Many groups are developing perfusion imaging
techniques for the characterization of human brain tumors (4,25,26,27). Early work in human
patients suggests that the information provided by vessel tortuosity measurements is different
from that given by perfusion imaging (15). We have not yet compared perfusion imaging to
vessel shape measurement in murine tumor models.
It may be initially surprising that a “malignancy probability” equation derived in human
subjects can be directly applied to the mouse. Fully testing this hypothesis would require
evaluation of a wide range of murine tumors, and is beyond the scope of the current report.
The fact the same equation appears to apply across species, however, can be explained if one
assumes that cancer induces the same vascular changes regardless of species or anatomical
region. Our approach normalizes each tumor subject’s vascular attribute values by the means
and standard deviations of the values obtained in the same anatomical region from healthy
subjects of the same species. Given this normalization, similar cancer-induced changes to the
underlying vasculature can then be recognized across species. Indeed, the fact that the same
equation appears relevant to both humans and the genetically engineered CPC model supports
the contention that the genetically engineered mouse model does indeed mimic human cancer
successfully. One of the most potentially important uses of vessel tortuosity analysis for
genetically engineered mouse tumor models is the early, noninvasive assessment of treatment
response a notoriously difficult problem in human patients. Furthermore, the similarity between
human and mouse tumor vessel characteristics suggests that the murine spontaneous cancer
models can indeed be utilized to refine imaging and mathematical analytical methods that are
applicable across species.
CONCLUSION
This report is, to our knowledge, the first to describe the MR imaging characteristics of a
genetically engineered, murine CPC tumor model during growth and progression. Furthermore,
although MRA imaging cannot display vessels at the capillary level, a statistical, quantitative
evaluation of vessel tortuosity based upon an equation derived from human subjects appears
effective in assessing malignancy for cancers larger than 0.3 – 1 mm3. Although much further
work is required, the approach appears to hold promise for the non-invasive assessment of
tumor staging and therapeutic monitoring.
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APPENDIX
Segmentation of vessels and of a region of interest
Vessels comprising the entire visible brain vasculature were segmented from the MRAs of all
healthy controls and from all genetically engineered animals. The vessel segmentation method
employs a semi-automated, multi-scale approach that proceeds from user-supplied seed points
to automatically define the path of each vessel and to calculate the radius at each vessel point
(28). This method models a vessel in three steps: (1) definition of a seed point on or near a
vessel of interest; (2) automatic, dynamic-scale extraction of an image intensity ridge
representing the vessel’s central skeleton; and (3) automatic determination of vessel radius at
each centerline point. During segmentation the vessel skeleton is set to a spline, and the output
defines each vessel as an ordered, regularly spaced set of x, y, z points indicating the spatial
position of that vessel’s centerline with an associated radius at each point. In this report, we
use the term “vessel” to indicate a single, unbranched structure.
Tumors were defined from T2 or T1-gadolinium enhanced images of tumor-bearing animals
using a program that defines tumors via polygon drawing and filling on orthogonal cuts through
an image volume. For animals in which no tumors or only very tiny tumors were evident, the
region of interest was defined as the contiguous space represented by the two lateral ventricles
and the third ventricle. If fewer than four vessels intersected the region of interest the region
was automatically dilated until four vessels were available for study.
Image registration
Our statistical approach to assessment of tumor malignancy requires mapping a region of
interest across subjects. Such mapping requires image registration.
For this study, we decided not to transform the vessels, as affine transformation might alter
measurements of tortuosity and other vessel attributes, but rather to deform the region of
interest across subjects. Vessels were thus analyzed only in their native states. All registrations
were performed using Rueckert and Schnabel’s mutual information-based registration program
(29,30). This program permits rigid, affine, and fully deformable registration. For rigid and
affine registrations, the output can be saved as a file convertible to a registration matrix. For
this project, we employed only rigid and full affine registrations and saved the output matrices.
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The MRA of each tumor subject was registered by full affine registration to the MRA image
of the first healthy mouse. The additional images of the tumor subject were then rigidly
registered to that same subject’s MRA. Lesion coordinates from any tumor subject could then
be transformed into the coordinate space of any subject’s MRA via a set of matrix
multiplications, using matrix inversion when appropriate. This approach requires only a single
registration per image, regardless of the number of images to which a region of interest may
be mapped.
Unlike human patients, mice with large tumors develop marked bulging of the skull.
Registration of such images with the MRA of a healthy mouse is difficult because the brain
and skull deform in mice with massive tumors whereas the jaw does not. We therefore
segmented the brains of all subjects, saving the output as greyscale images, and performed the
registration using only the brain. Following registration, vessels traversing the region of interest
were clipped to that surface, and analysis was performed only upon vessel segments confined
to the region of interest.
Statistical analysis
In human beings (and presumably also the mouse), vessel density, tortuosity, average radius,
and a variety of other measures of vessel shape vary from location to location within the head
(31). It is therefore not possible to define a single definition of “healthy” vessel morphology.
The vessel shape changes induced by malignancy and other focal disease processes must
therefore be interpreted within the context of the expected vessel shape measures within the
affected region.
We therefore normalized each tumor vessel attribute by the means and standard deviations of
the healthy measures derived from the same anatomical region of healthy controls of the same
species. Each value was represented as a z-score, and all further statistical processing was
performed upon these z-scored values. For example, the z-scored SOAM value for a mouse
tumor was given by:
A further advantage of this approach is that, since we employ averages of averages, the
normality assumption of the measurements is plausible by the central limit theorem.
In human patients, a previous blinded study analyzed a variety of vessel shape measures from
MRA images of both benign and malignant brain tumors, using z-score values as outlined
above (17). Using these z-score values, three methods including linear discriminant analysis,
quadratic discriminant analysis, and nonparametric classification trees were employed to select
the classification rule most effective in separating benign from malignant tumors. All three
methods identified SOAM and ICM as the only important factors and resulted in similar
classification error rates. Therefore, only the results of the linear discrimant analysis, the
simplest classification rule, were employed.
More specifically, two equations were derived from the zscored SOAM and ICM values by
linear discriminant analysis. The first equation below represented the summarized mean
measure for the malignant group. The second equation represented the summarized mean
measure for the benign group.
Bullitt et al. Page 11













The probability of malignancy was then
This equation provides a continuous measure with values between 0 and 1, in which higher
values indicate a higher probability of malignancy. Multiplying by 100 provides an estimate
of malignancy as a percentage. In general, this equation indicates that the parameters important
to detecting the vessel shape abnormalities of malignancy are the two tortuosity measures, with
SOAM (which detects high-frequency “wiggles”) of more importance than the ICM (which
detects wider excursion curves).
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Choroid dysplasia. Top row: From left to right, coronal T1, T2, T1-GAD, and MRA slices.
Bottom row: Left: H & E stained coronal histological section. Bar = 200 μm. Note the thickened
and somewhat disorganized choroid at left (arrows). Center and right: 3D segmented vessels
with the ventricular system shown at full opacity (center) and no opacity (right). Vessels are
shown from an AP view and are color-coded relative to the ventricular system with
blue=outside, gold=traverse, red = inside, cyan = exit or enter. Vessel analysis was performed
upon all red vessels and upon the segments of the gold and cyan vessels lying within the region
of interest. This case is tumor 19 in Table 1.
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Emerging cancer. Top row from left to right: T1, T2, T1-GAD, and MRA slices. Arrow points
to multiple, tiny cancers visible in the T2 image. Bottom row: Left: H & E histological section.
Note the tiny cancer foci (arrows). Bar = 200 μm. Center and right: 3D rendering of segmented
vessels with the segmented ventricular system shown at full (center) and no (right) opacity
from an AP view. Vessel color coding is as outlined in Figure 2. This case is tumor 15 in Table
1.
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Typical vessel tortuosity abnormality in one of the CPC mice during early cancer development.
Note the “many bends upon each larger bend” present in the highlighted (red) vessel.
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Terminal CPC tumor. Top row: a massive tumor is shown from left to right in T1, T2, T1-
GAD, and MRA slices. The arrow points to the tumor as seen on T1-Gad. The contralateral
ventricular system is dilated. Bottom row: Left: H & E histological slice from this animal. Bar
= 200 μm. Center and right: 3D rendering of an AP view of segmented vessels and with the
segmented tumor shown at full (center) and no (right) opacity. Vessel color coding is outlined
in Figure 2. This tumor is case 5 in Table 1.
Bullitt et al. Page 16































































































































































































































































































































































































































































































































































































































































































































AJNR Am J Neuroradiol. Author manuscript; available in PMC 2008 August 11.
